Breaking News Instant updates and real-time market news.

VTL

Vital Therapies

$8.70

-0.15 (-1.69%)

16:08
08/07/18
08/07
16:08
08/07/18
16:08

Vital Therapies reports Q2 EPS (30c), consensus (33c)

The Company expects to report topline data from its VTL-308 pivotal clinical trial in the second half of September 2018. VTL-308 is the Company's phase 3 randomized, controlled, open-label trial, designed to evaluate the ELAD System in subjects with severe alcoholic hepatitis VTL-308 completed enrollment at the end of March 2018 with 151 subjects (78 in ELAD-treated arm, 73 in control arm) enrolled at 38 sites in the United States and European Union. Cash and cash equivalents at June 30, 2018, totaled $31.1 million compared to $56.9 million at December 31, 2017. The Company expects its use of funds will change based on the results of the VTL-308 clinical trial.

  • 07

    Aug

VTL Vital Therapies
$8.70

-0.15 (-1.69%)

08/06/18
WBLR
08/06/18
UPGRADE
WBLR
Outperform
Vital Therapies upgraded to Outperform from Market Perform at William Blair
William Blair analyst Y. Katherine Xu upgraded Vital Therapies to Outperform ahead of the VTL-308 readout in September. VTL-308 is the company's Phase 3 trial designed to evaluate its Elad System in subjects with severe alcoholic hepatitis.
08/06/18
WBLR
08/06/18
UPGRADE
WBLR
Outperform
William Blair upgrades Vital Therapies to Outperform with $35 fair value
William Blair analyst Y. Katherine Xu upgraded Vital Therapies to Outperform from Market Perform and raised her fair value estimate for the shares to $35 from $10. Top-line data from the pivotal VTL-308 study of the company's Elad, or extracorporeal liver-assist device, versus standard of care in severe acute alcoholic hepatitis is expected in September, Xu tells investors in a research note. The analyst views the readout as a key binary event for both Vital Therapies shares and the acute liver failure field. She raised her probability of success of VTL-308 to 70% from 55% and upped her global peak sales estimate to $1.5B from $850M for Elad. VTL-308's primary endpoint is overall survival, and should the study be successful, it is highly likely that Elad becomes the standard of care for this population of patients over time, Xu contends.

TODAY'S FREE FLY STORIES

MS

Morgan Stanley

$48.32

-0.06 (-0.12%)

16:01
08/20/18
08/20
16:01
08/20/18
16:01
Hot Stocks
Morgan Stanley Energy Partners, Catalyst Energy form strategic partnership »

Investment funds managed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Sep

IO

ION Geophysical

$16.65

0.05 (0.30%)

15:58
08/20/18
08/20
15:58
08/20/18
15:58
Hot Stocks
Breaking Hot Stocks news story on ION Geophysical »

Rajay Bagaria reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CTX

Centex

$25.26

1.92 (8.23%)

15:57
08/20/18
08/20
15:57
08/20/18
15:57
Hot Stocks
Breaking Hot Stocks news story on Centex 

Qwest trading resumes

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

15:57
08/20/18
08/20
15:57
08/20/18
15:57
Hot Stocks
Breaking Hot Stocks news story  

Qwest trading resumes

PAY

Verifone

$23.04

(0.00%)

15:57
08/20/18
08/20
15:57
08/20/18
15:57
Hot Stocks
Breaking Hot Stocks news story on Verifone 

Verifone trading resumes

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CTU

Chad Therapeutics, Inc.

$25.26

1.925 (8.25%)

15:57
08/20/18
08/20
15:57
08/20/18
15:57
Hot Stocks
Breaking Hot Stocks news story on Chad Therapeutics, Inc. 

Qwest trading resumes

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PCG

PG&E

$44.80

-0.44 (-0.97%)

, EIX

Edison International

$69.24

-0.62 (-0.89%)

15:56
08/20/18
08/20
15:56
08/20/18
15:56
Periodicals
California plan could let PG&E issue bonds to cover fire damages, Bloomberg says »

California Senator Bill…

PCG

PG&E

$44.80

-0.44 (-0.97%)

EIX

Edison International

$69.24

-0.62 (-0.89%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

BPY

Brookfield Property

$19.90

-0.19 (-0.95%)

15:55
08/20/18
08/20
15:55
08/20/18
15:55
Options
Brookfield Property put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

VERI

Veritone

$11.25

-0.16 (-1.40%)

15:55
08/20/18
08/20
15:55
08/20/18
15:55
Conference/Events
Veritone to hold a conference call »

Management discusses the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Aug

CBS

CBS

$53.67

0.45 (0.85%)

15:46
08/20/18
08/20
15:46
08/20/18
15:46
Periodicals
Court revives copyright suit against CBS over pre-1972 recordings, Reuters says »

CBS is facing a lawsuit…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Sep

  • 27

    Sep

TSLA

Tesla

$304.35

-0.98 (-0.32%)

15:42
08/20/18
08/20
15:42
08/20/18
15:42
Periodicals
Some Tesla suppliers worry about getting paid, WSJ reports »

Some Tesla suppliers have…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

FIT

Fitbit

$6.02

0.315 (5.52%)

15:37
08/20/18
08/20
15:37
08/20/18
15:37
Hot Stocks
Fitbit announces Fitbit Charge 3 »

Earlier today, Fitbit…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Sep

NDSN

Nordson

$134.72

-0.07 (-0.05%)

15:34
08/20/18
08/20
15:34
08/20/18
15:34
Options
Nordson options imply 7.8% move in share price post-earnings, below median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

GOOG

Alphabet

$1,207.00

7.21 (0.60%)

, GOOGL

Alphabet Class A

$1,222.10

6.6 (0.54%)

15:31
08/20/18
08/20
15:31
08/20/18
15:31
Periodicals
Google, IMAX VR project quietly canceled, Variety reports »

A joint virtual reality…

GOOG

Alphabet

$1,207.00

7.21 (0.60%)

GOOGL

Alphabet Class A

$1,222.10

6.6 (0.54%)

IMAX

Imax

$22.80

0.4 (1.79%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

  • 22

    Aug

  • 06

    Sep

  • 06

    Sep

  • 18

    Sep

  • 20

    Sep

  • 28

    Oct

STAA

STAAR Surgical

$42.05

1.1 (2.69%)

15:24
08/20/18
08/20
15:24
08/20/18
15:24
Conference/Events
STAAR Surgical management to meet with William Blair »

Meeting to be held in Los…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Aug

  • 22

    Aug

SRI

Stoneridge

$32.61

0.39 (1.21%)

15:23
08/20/18
08/20
15:23
08/20/18
15:23
Hot Stocks
Stoneridge appoints Laurent Borne as Chief Technology Officer »

Stoneridge announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Sep

  • 29

    Oct

  • 06

    Nov

DVA

DaVita

$72.44

-0.05 (-0.07%)

15:22
08/20/18
08/20
15:22
08/20/18
15:22
Conference/Events
DaVita management to meet with William Blair »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Aug

ALTR

Altair

$40.63

0.4 (0.99%)

15:20
08/20/18
08/20
15:20
08/20/18
15:20
Conference/Events
Altair management to meet with William Blair »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

  • 22

    Aug

  • 12

    Sep

CBOE

Cboe Global Markets

$98.72

2.96 (3.09%)

15:20
08/20/18
08/20
15:20
08/20/18
15:20
Options
Sweep buyer of CBOE calls »

Sweep buyer of CBOE…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FANH

Fanhua

$25.76

0.53 (2.10%)

15:19
08/20/18
08/20
15:19
08/20/18
15:19
Options
Fanhua options imply 7.4% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Aug

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

15:17
08/20/18
08/20
15:17
08/20/18
15:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

15:16
08/20/18
08/20
15:16
08/20/18
15:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XRAY

Dentsply Sirona

$38.84

0.17 (0.44%)

15:12
08/20/18
08/20
15:12
08/20/18
15:12
Conference/Events
Dentsply Sirona management to meet with William Blair »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

  • 27

    Sep

  • 06

    Nov

STZ

Constellation Brands, also tag STZ.B

$202.74

-1.16 (-0.57%)

15:11
08/20/18
08/20
15:11
08/20/18
15:11
Options
Repeat call spreads in Constellation Brands »

Repeat call spreads in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Oct

LCI

Lannett

$5.43

-8.075 (-59.81%)

, AMRX

Amneal Pharmaceuticals

$23.86

2.33 (10.82%)

15:08
08/20/18
08/20
15:08
08/20/18
15:08
Recommendations
Lannett, Amneal Pharmaceuticals analyst commentary  »

Lannett price target…

LCI

Lannett

$5.43

-8.075 (-59.81%)

AMRX

Amneal Pharmaceuticals

$23.86

2.33 (10.82%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Aug

  • 28

    Aug

  • 05

    Sep

  • 12

    Sep

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.